Gilead Signs a Co-Promotion Agreement with Eisai for Filgotinib in Japan
Shots:
- Gilead collaborates with Eisai to distribute & co-promote filgotinib for RA. Gilead will be accountable for manufacturing and approval of filgotinib while Eisai will be responsible for distribution in Japan for RA and other future indications
- Following the approval- the companies will jointly commercialize filgotinib. The agreement will extend to additional potential indications for filgotinib including UC- CD and PsA
- Filgotinib is an investigational- oral- selective JAK1 inhibitor with its pending approval for RA in Japan- currently being evaluated in P-III SELECTION- DIVERSITY- PENGUIN study for UC- CD- PsA and P-II studies for uveitis & in the small bowel and fistulizing CD respectively
Click here to read full press release/ article
Ref: Gilead | Image: Gilead
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com